Radiopharmaceuticals market to hit $24.1b by 2034 as chronic cases rise

APAC is witnessing significant growth supported by investments, amongst others.

The radiopharmaceuticals market is projected to reach US$24.1b by 2034, with a compound annual growth rate of 10%, according to a DelveInsight report.

This will be driven by the rising incidence of chronic illnesses, nuclear medicine advancements, demand for personalised medicine, and favourable policy support.

North America (42%) held the largest share of the market in 2025, attributed to the increasing incidence of cancer and cardiovascular disorders.

In the Asia-Pacific region, the market is witnessing significant growth, supported by investments, improvements in diagnostic infrastructure, and the growing utilisation of advanced imaging technologies.